This paper deals with the subject of corporate reputation in the U.S. Pharmaceutical sector and whether the allocation of dedicated resource to its management has measurable benefits to the enhancement of that reputation.
[download id=”432″]
Kimberley Goldstein, John Doorley, Paul Turner
April 2011
